Share this article and save a life!
One image. One second. One life-saving cardiac diagnosis.
Mayo Clinic just changed the game for cardiac care.
Their new AI estimates left ventricular ejection fraction (LVEF) from a single echocardiogram frame, not video. Published in The Lancet Digital Health this month, this breakthrough means faster cardiac assessments anywhere, anytime.
Think about what this means:
• Rural emergency rooms without cardiac specialists
• Bedside evaluations in critical moments
• Point-of-care ultrasounds in resource-limited settings
• Faster triage decisions when seconds count
Yes, single-frame analysis is less accurate than video. But here’s the thing: perfect accuracy in a cardiac lab doesn’t help the patient 200 miles away having chest pain at 2 AM.
This isn’t Mayo’s first cardiac AI win either. They’ve already FDA-approved algorithms for detecting heart failure with preserved ejection fraction (73.6% accuracy reclassifying indeterminate cases) and cardiac amyloidosis (85% sensitivity, 93% specificity).
💡 The real innovation here isn’t just the technology, it’s the philosophy: democratizing advanced diagnostics by making them simpler, faster, and more accessible.
We keep talking about health equity. This is what it looks like in practice.
When a single ultrasound image can reveal critical cardiac function, we’re not just advancing technology, we’re expanding access to life-saving diagnostics for millions who need it most.
The question isn’t whether AI will transform cardiac care. It’s whether our health systems are ready to deploy these tools where they’re needed most: at the bedside, in the ambulance, in the rural clinic.
Because technology that only works in academic medical centers isn’t revolutionary. Technology that works everywhere? That changes everything.
♻️ Repost if cardiac diagnostics should be available everywhere, not just major medical centers.
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
